Data Output

What our 10-second scan actually produces

QuadraScan captures a full set of anthropometric and body-composition measurements instantly. Below is a sample of how that data gets put to work across different verticals.

Sports

Stop mistaking early development for better talent.

Growth and maturation can dramatically influence how young athletes look and perform today. QuadraScan gives organizations the body intelligence to understand where an athlete is now, and where they’re heading.

Track maturation, PHV, predicted height, body composition and longitudinal development at the individual level. Then benchmark across teams, age groups and cohorts to put performance in biological context.

Identify

Late-developing athletes who may otherwise be overlooked.

Benchmark

Understand athletes relative to teammates and comparable cohorts.

Track

See how bodies change across a season—not just on assessment day.

Athlete
Jordan E.
Age / Sex
16, Male
Scans
3
Window
Jun–Aug 2026
Maturation
Avg–Late
Weight
154 lb
+5 lb since baseline
Lean Mass
55.8 kg
Tracked across 3 scans
PHV Age
14.4 yr
Peak growth marker
Pred. Adult Height
5'11.5"
Holding steady
Average to Late Maturer
PHV timing: within ±0.5 years of average · PHV cut-off: 12.75–14.75 yrs (~13.8 avg)

Jordan's estimated PHV age (14.4) sits slightly behind the median for his age group. Some of the physical gap versus early-maturing peers is timing, not talent. The kind of signal that keeps late bloomers from getting cut too early.

Scan
Height
Weight
BMI
BRI
WHtR
Lean Mass
Fat Mass
Bone Min.
Jun 25
5'10"
149 lb
21.4
2.2
0.41
58.3 kg
6.8 kg
2.95 kg
Jul 3
5'10"
149 lb
21.4
2.2
0.42
56.5 kg
9.1 kg
2.48 kg
Aug 21
5'10"
154 lb
22.1
2.6
0.45
55.8 kg
11.8 kg
2.51 kg
Sports Benchmarking

One athlete tells you something. A population tells you more.

Turn individual scans into organizational intelligence.

Benchmark athletes by age, cohort, team or population to understand distributions, identify outliers and establish more meaningful developmental context.

Soccer — Body Maturation Benchmarking ReportSample data
386Total Scans
8Measurements
4Age Groups
U15–U18Range
PHV Age — Median & IQR by Age Group

Line marker = median PHV age · shaded band = interquartile range (P25–P75) · scale 13.0–15.0 yr

U15
Median 13.80 yr · IQR 13.38–14.30
U16
Median 13.96 yr · IQR 13.50–14.31
U17
Median 14.46 yr · IQR 13.90–14.88
U18
Median 13.75 yr · IQR 13.47–14.04
Key Anthropometric Trends — Median (U15 → U17)
Measurement
U15 → U17
Median Δ
Weight (kg)
63.3 → 71.2
+12.5%
PHV Age (yr)
13.80 → 14.46
+4.8%
Avg Leg Length (in)
35.8 → 37.2
+4.0%
Avg Calf Circ (in)
13.87 → 14.37
+3.6%
Height (cm)
172.2 → 177.2
+2.9%
Seated Height (in)
34.9 → 35.9
+2.7%
Mid Thigh Circ (in)
18.52 → 18.93
+2.2%
Recreated from a live fit:match benchmarking report — view the full interactive sample

Sample athlete, name changed and figures lightly adjusted. Benchmarking data from a 386-scan soccer demo dataset.

Parent & GROWTH INSIGHTS

Give parents more than measurements. Give them context.

Turn every scan into an easy-to-understand view of a child’s growth and development with measurements, body composition, maturation and growth insights brought together in one personalized experience.

Understand Today

Height, measurements and body composition.

See Development In Context

Maturity status, PHV and cohort comparisons.

Look Ahead

Growth modeling and predicted adult height.

Follow The Journey

Repeat scans create a longitudinal view of development over time.

Name
Isaac T.
Age / Sex
10, Male
Scan Date
Aug 26, 2026
Height
4' 7"
Weight
72 lbs
BMI: 16.7
CURRENT · 16.7
≤ 18.518.5–24.925.0–29.9≥ 30.0

BMI shown reflects percentile-for-age, not adult weight categories.

BRI: 2.6
CURRENT · 2.6
≤ 22–44–6≥ 6
Waist-to-Height Ratio: 0.45
CURRENT · 0.45
≤ 0.50.50–0.590.60–0.69≥ 0.70
Average Maturer
PHV timing: within ±0.5 years of average · PHV: 13.2 yrs

This athlete is estimated to reach peak growth in about 3.2 years. Training can continue building a broad athletic base, with strength/skill work phased in as he approaches peak growth.

Estimated Age at PHV: 13.2
YOU · 13.2
EarlyAverageLate
Measurement
This Athlete
Team Avg
fit:match Avg
Similar Cohorts
Weight (lb)
72.0
129.1
144.7
106.1
BMI
16.7
21.5
22.5
22.3
Body Roundness Index
2.6
3.3
3.6
3.9
Chest (in)
27.5
37.4
37.9
33.5
Waist (in)
25.0
32.1
35.3
31.5
Hip (in)
36.5
38.4
40.5
34.4
Waist-to-Hip Ratio
0.9
0.8
0.8
0.9
Waist-to-Height Ratio
0.45
0.5
0.5
0.5
These figures are AI-generated estimates built on internal research and DEXA-trained models. They are informational only. Families can review the underlying benchmarks against CDC, NIH, NICE, and Yale Medicine references, or reach us at cs@fitmatch.ai.
HEALTH & WELLNESS TRACKING

Weight loss doesn’t tell you what was lost. We do.

A scale shows one number. QuadraScan shows what is changing underneath it.

Track fat mass, lean mass, body measurements and longitudinal change throughout a weight-management journey. We give patients, providers and organizations a richer view of progress than weight or BMI alone.

Patient ID
GLP-84210
Medication
Semaglutide
Scans
25
Window
Oct 2024–Feb 2026
Weeks on Therapy
~69
Fat Mass
73.0 lb
−9.4 lb (−11.4%)
Lean Mass
113.0 lb
+4.6 lb (+4.2%)
BMI
28.6
from 33.6
Waist (narrowest)
36.7"
from 40.1"
Fat Mass vs. Lean Mass
25 scans, Oct 2024–Feb 2026. Fat trending down while lean holds and gains.
BMI vs. Dose Timeline
BMI plotted against the semaglutide dosing schedule. Step-line shows dose changes.
Waist & Hip Circumference
Where the inches came off. Waist −3.4", hip −5.4" over the treatment window.
Date
Medication
Dose
Change
Notes
10/02/24
Semaglutide
0.25 mg
Start
Initiated therapy
11/06/24
Semaglutide
0.5 mg
Increase
Tolerating well
01/02/25
Semaglutide
1.0 mg
Increase
Per protocol
02/20/25
Semaglutide
1.7 mg
Increase
Dose escalation
04/03/25
Semaglutide
2.4 mg
Increase
Maintenance reached
11/06/25
Semaglutide
2.4 mg
Same
Resumed after gap
01/08/26
Semaglutide
1.7 mg
Decrease
GI side effects
15.3%
body weight loss over 68 weeks, semaglutide 2.4mg/week
STEP 1 · Wilding et al., NEJM 2021
20.9%
body weight loss over 72 weeks, tirzepatide 15mg/week
SURMOUNT-1 · Jastreboff et al., NEJM 2022
8.0%
body weight loss over 56 weeks, liraglutide 3.0mg/day
SCALE Obesity · Pi-Sunyer et al., NEJM 2015

Sample patient journey for illustration. Individual results vary.